Granules India shines on receiving EIR from USFDA for its Chantilly facility

28 Feb 2018 Evaluate

Granules India is currently trading at Rs. 117.80, up by 0.55 points or 0.47% from its previous closing of Rs. 117.25 on the BSE.

The scrip opened at Rs. 116.00 and has touched a high and low of Rs. 119.05 and Rs. 114.90 respectively. So far 71779 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 157.00 on 18-May-2017 and a 52 week low of Rs. 101.95 on 11-Aug-2017.

Last one week high and low of the scrip stood at Rs. 120.25 and Rs. 112.40 respectively. The current market cap of the company is Rs. 2948.32 crore.

The promoters holding in the company stood at 44.94%, while Institutions and Non-Institutions held 18.36% and 36.70% respectively.

The US Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) for Granules Pharmaceuticals, Inc. facility, a wholly-owned foreign subsidiary of Granules India located in Chantilly, Virginia, USA.

This facility was inspected by USFDA in December 2017 and there was one observation during the inspection. The company has responded to the observation within the stipulated timeframe.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

593.90 -12.00 (-1.98%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.